Literature DB >> 14736250

Potent and selective conformationally restricted neuronal nitric oxide synthase inhibitors.

José A Gómez-Vidal1, Pavel Martásek, Linda J Roman, Richard B Silverman.   

Abstract

Selective inhibition of the isoforms of nitric oxide synthase (NOS) in pathologically elevated synthesis of nitric oxide has great therapeutic potential. We previously reported nitroarginine-containing dipeptide amides and some peptidomimetic analogues as potent and selective inhibitors of neuronal NOS (nNOS). Here we report conformationally restricted dipeptides derived from the dipeptide L-Arg(NO2)-L-Dbu-NH2 (8). The selectivities for nNOS over endothelial NOS and inducible NOS of the most potent nNOS inhibitor (10a) among these compounds are comparable to that of the parent compound. An unsubstituted amide bond is necessary for potency against nNOS. The stereochemistry of compound 10a was optimum for potency and selectivity and thus provides the binding conformation of the parent compound with nNOS.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14736250     DOI: 10.1021/jm030297m

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  14 in total

1.  Unexpected binding modes of nitric oxide synthase inhibitors effective in the prevention of a cerebral palsy phenotype in an animal model.

Authors:  Silvia L Delker; Haitao Ji; Huiying Li; Joumana Jamal; Jianguo Fang; Fengtian Xue; Richard B Silverman; Thomas L Poulos
Journal:  J Am Chem Soc       Date:  2010-04-21       Impact factor: 15.419

2.  Crystal structures of constitutive nitric oxide synthases in complex with de novo designed inhibitors.

Authors:  Jotaro Igarashi; Huiying Li; Joumana Jamal; Haitao Ji; Jianguo Fang; Graham R Lawton; Richard B Silverman; Thomas L Poulos
Journal:  J Med Chem       Date:  2009-04-09       Impact factor: 7.446

3.  Conformationally restricted dipeptide amides as potent and selective neuronal nitric oxide synthase inhibitors.

Authors:  Haitao Ji; José A Gómez-Vidal; Pavel Martasek; Linda J Roman; Richard B Silverman
Journal:  J Med Chem       Date:  2006-10-19       Impact factor: 7.446

4.  Structural basis for isoform-selective inhibition in nitric oxide synthase.

Authors:  Thomas L Poulos; Huiying Li
Journal:  Acc Chem Res       Date:  2012-10-02       Impact factor: 22.384

5.  Selective neuronal nitric oxide synthase inhibitors and the prevention of cerebral palsy.

Authors:  Haitao Ji; Sidhartha Tan; Jotaro Igarashi; Huiying Li; Matthew Derrick; Pavel Martásek; Linda J Roman; Jeannette Vásquez-Vivar; Thomas L Poulos; Richard B Silverman
Journal:  Ann Neurol       Date:  2009-02       Impact factor: 10.422

Review 6.  Target- and mechanism-based therapeutics for neurodegenerative diseases: strength in numbers.

Authors:  Paul C Trippier; Kristin Jansen Labby; Dustin D Hawker; Jan J Mataka; Richard B Silverman
Journal:  J Med Chem       Date:  2013-03-27       Impact factor: 7.446

7.  Nitric oxide synthases activation and inhibition by metallacarborane-cluster-based isoform-specific affectors.

Authors:  Robert Kaplánek; Pavel Martásek; Bohumír Grüner; Satya Panda; Jakub Rak; Bettie Sue Siler Masters; Vladimír Král; Linda J Roman
Journal:  J Med Chem       Date:  2012-11-01       Impact factor: 7.446

Review 8.  Development of nitric oxide synthase inhibitors for neurodegeneration and neuropathic pain.

Authors:  Paramita Mukherjee; Maris A Cinelli; Soosung Kang; Richard B Silverman
Journal:  Chem Soc Rev       Date:  2014-10-07       Impact factor: 54.564

9.  Discovery of highly potent and selective inhibitors of neuronal nitric oxide synthase by fragment hopping.

Authors:  Haitao Ji; Huiying Li; Pavel Martásek; Linda J Roman; Thomas L Poulos; Richard B Silverman
Journal:  J Med Chem       Date:  2009-02-12       Impact factor: 7.446

Review 10.  Design of selective neuronal nitric oxide synthase inhibitors for the prevention and treatment of neurodegenerative diseases.

Authors:  Richard B Silverman
Journal:  Acc Chem Res       Date:  2009-03-17       Impact factor: 22.384

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.